Moderna’s novel coronavirus vaccine (mRNA-1273) is a front-running candidate to be one of the first available to market. If successful, the vaccine would also be the world’s ...
author: Johnathan Ritucci
The U.S. Food and Drug Administration (FDA) recently approved Gilead’s antiviral Remdesivir for emergency use authorization (EUA) as a treatment for COVID-19 in severe stages. ...
author: Johnathan Ritucci
Through partnerships with the world’s premier investment research organizations, Visible Alpha enhances the investment research process by extracting meaningful value from key sell-side assets, including analyst models, research reports and corporate access events. Our deep consensus data provides a quick understanding of the sell-side view on companies and industries at a level of granularity, timeliness and interactivity that has never before been possible.
Facebook
LinkedIn
Twitter© 2022 Visible Alpha, LLC. All rights reserved.
